In the Bubble with Andy Slavitt cover image

Are We on the Verge of Curing Alzheimer’s?

In the Bubble with Andy Slavitt

CHAPTER

Adicannemap - What's Controversy?

Adicannemap is an antibody that attacks amyloid deposits in brain. FDA and Medicare had to make a decision on whether the drug should be approved. Adjelm has caused some controversy, but it's not clear if there are any problems with its safety or effectiveness.

00:00
Transcript
Play full episode

Remember Everything You Learn from Podcasts

Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
App store bannerPlay store banner